Why Traders Flocked to These 10 Stocks on Monday

2. CG Oncology, Inc. (NASDAQ:CGON)

CG Oncology grew its share prices for a fifth straight day on Monday, surging 25.03 percent to end at $27.97 apiece as investors cheered the promising results of its bladder cancer treatment that could rival Johnson & Johnson’s.

Following a two-year study, CG Oncology, Inc. (NASDAQ:CGON) said that cretostimogene grenadenorepvec—its investigational monotherapy for high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG treatment— reported a robust 42.3 percent response rate and 97.3 percent non-progression to muscle-invasive disease.

Additionally, 91.6 percent of the enrollees retained their ability to avoid cystectomy.

The treatment, which could rival Johnson & Johnson’s own bladder cancer treatment, demonstrated a high degree of safety without adverse effects reported.

Following the announcement, Cantor Fitzgerald reiterated its Overweight rating for CG Oncology, Inc. (NASDAQ:CGON) alongside a price target of $75, or a 168-percent upside from its latest closing price.